Rice Hall James & Associates LLC grew its position in Amdocs Limited (NASDAQ:DOX - Free Report) by 338.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 167,023 shares of the technology company's stock after buying an additional 128,919 shares during the quarter. Rice Hall James & Associates LLC owned 0.14% of Amdocs worth $14,611,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also modified their holdings of the company. State Board of Administration of Florida Retirement System grew its stake in shares of Amdocs by 7.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 166,927 shares of the technology company's stock valued at $16,030,000 after buying an additional 12,178 shares in the last quarter. Boston Trust Walden Corp grew its stake in Amdocs by 17.0% during the 2nd quarter. Boston Trust Walden Corp now owns 618,387 shares of the technology company's stock worth $48,803,000 after purchasing an additional 89,726 shares in the last quarter. SG Americas Securities LLC grew its stake in Amdocs by 402.4% during the 2nd quarter. SG Americas Securities LLC now owns 154,968 shares of the technology company's stock worth $12,230,000 after purchasing an additional 124,122 shares in the last quarter. Sargent Investment Group LLC acquired a new position in Amdocs during the 2nd quarter worth $289,000. Finally, Acadian Asset Management LLC grew its stake in Amdocs by 22.7% during the 1st quarter. Acadian Asset Management LLC now owns 1,395,894 shares of the technology company's stock worth $126,119,000 after purchasing an additional 258,343 shares in the last quarter. 92.02% of the stock is owned by institutional investors and hedge funds.
Amdocs Stock Up 0.5 %
NASDAQ DOX traded up $0.46 during trading on Friday, reaching $88.21. 187,267 shares of the company's stock were exchanged, compared to its average volume of 669,748. The stock has a market cap of $10.37 billion, a P/E ratio of 20.22, a price-to-earnings-growth ratio of 1.43 and a beta of 0.74. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.24 and a current ratio of 1.24. The company has a 50 day moving average price of $87.36 and a two-hundred day moving average price of $83.65. Amdocs Limited has a 1 year low of $74.41 and a 1 year high of $94.04.
Amdocs (NASDAQ:DOX - Get Free Report) last posted its earnings results on Wednesday, August 7th. The technology company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.02. Amdocs had a return on equity of 17.89% and a net margin of 10.21%. The business had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the business earned $1.41 EPS. The business's quarterly revenue was up 1.1% on a year-over-year basis. On average, equities research analysts anticipate that Amdocs Limited will post 5.67 EPS for the current fiscal year.
Amdocs Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Monday, September 30th were issued a $0.479 dividend. This represents a $1.92 annualized dividend and a dividend yield of 2.17%. The ex-dividend date was Monday, September 30th. Amdocs's payout ratio is currently 44.24%.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. StockNews.com raised Amdocs from a "buy" rating to a "strong-buy" rating in a research note on Friday, October 25th. Stifel Nicolaus initiated coverage on Amdocs in a research note on Wednesday, October 2nd. They set a "buy" rating and a $100.00 target price for the company. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $102.00.
Read Our Latest Stock Report on Amdocs
About Amdocs
(
Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Featured Articles
Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
